EP Patent

EP4215184A1 — Trabectedin composition

Assigned to Extrovis AG · Expires 2023-07-26 · 3y expired

What this patent protects

The present disclosure provides a stable, ready-to-dilute injectable pharmaceutical composition comprising trabectedin and at least one pharmaceutically acceptable excipient, wherein the composition is free of ethanol.

USPTO Abstract

The present disclosure provides a stable, ready-to-dilute injectable pharmaceutical composition comprising trabectedin and at least one pharmaceutically acceptable excipient, wherein the composition is free of ethanol.

Drugs covered by this patent

Patent Metadata

Patent number
EP4215184A1
Jurisdiction
EP
Classification
—
Expires
2023-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Extrovis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.